Core Viewpoint - The article discusses the development of a novel mRNA cancer vaccine utilizing membrane-destabilizing zwitterionic lipids, which addresses two major challenges: limited mRNA expression and unavoidable inflammatory responses [2][4]. Group 1: Research Development - A research team led by Professor Jiang Shaoyi from Cornell University published a study in Nature Biomedical Engineering, highlighting a new mRNA cancer vaccine that exhibits low reactogenicity and high tumor antigen expression [3]. - The study introduces a membrane-destabilizing zwitterionic lipid that enhances mRNA expression by promoting endosomal escape while simultaneously reducing inflammatory responses [6]. Group 2: Lipid Characteristics - The zwitterionic lipid features a pyridinium carboxybetaine (PyCB) head group, a biodegradable multi-tail alkyl chain, and a tertiary amine linker, which allows for effective protonation and biocompatibility under physiological pH conditions [6]. - The PyCB head group forms a zwitterionic PyCB-water complex, which becomes positively charged at pH levels below 6.8, facilitating efficient mRNA release in endosomes [6]. Group 3: Enhanced Vaccine Efficacy - Incorporating this zwitterionic lipid into commercial mRNA vaccine LNP formulations significantly increases mRNA expression levels in antigen-presenting cells within lymph nodes, thereby enhancing cytotoxic T cell activation [7]. - The zwitterionic nature of the lipid results in reduced inflammatory responses and neutrophil infiltration at the injection site, providing an advantage for the nanoparticles containing this lipid [7]. - This lipid is also compatible with existing targeted nanoparticle formulations, which can further optimize mRNA delivery efficiency [7].

Core Viewpoint - mRNA vaccines have shown strong clinical efficacy in preventing COVID-19, which has spurred the development of mRNA cancer vaccines as a promising strategy to elicit robust and specific anti-tumor immune responses [2][3]. Group 1: Research Development - The research team from Fudan University developed a novel single-component lipid-mRNA delivery system called OncoLRC, which efficiently targets mRNA delivery to splenic antigen-presenting cells, activating a strong anti-tumor immune response [3][11]. - Traditional lipid nanoparticles (LNPs) used in mRNA vaccines have a significant limitation of accumulating in the liver after systemic administration, prompting researchers to focus on developing splenic-targeting mRNA-LNP delivery systems [4][11]. Group 2: Mechanism and Efficacy - OncoLRC demonstrates nearly exclusive splenic targeting for mRNA delivery, outperforming traditional four-component LNP formulations, with in vivo experiments showing that mRNA is predominantly expressed in splenic antigen-presenting cells after intravenous injection [6][11]. - The OncoLRC formulation requires a lipid-to-mRNA weight ratio of 1.5:1, compared to the typical 10:1 ratio in standard LNPs, which enhances the maturation and activation of dendritic cells, leading to a strong antigen-specific immune response [8][9]. Group 3: Clinical Implications - Mechanistic studies indicate that the splenic delivery of OncoLRC is mediated primarily through macropinocytosis, enhancing the secretion of endogenous cytokines like IL-12, which further stimulates T cell activation and cytotoxic activity [9]. - In a B16F10-OVA cold tumor model, OncoLRC demonstrated significant preventive anti-tumor efficacy and exhibited a notable synergistic effect when combined with immune checkpoint blockade therapy, effectively inhibiting tumor growth [9][11].

Core Viewpoint - The study reveals that newly evolved human de novo genes, crucial for brain development and cognitive function, may also promote cancer, leading to the development of mRNA cancer vaccines that effectively stimulate anti-tumor immune responses and significantly inhibit tumor growth [3][9]. Group 1: Research Findings - The research identified 37 de novo genes with clear evolutionary trajectories unique to humans and their close primate relatives [5][7]. - These de novo genes exhibit increased expression in tumors, with 57.1% of their deletions suppressing tumor cell proliferation, indicating their oncogenic roles [5][7]. - The study highlights two specific de novo genes, ELFN1-AS1 and TYMSOS, which are expressed during early human development but reactivated in tumors, suggesting their potential as therapeutic targets [5][6]. Group 2: Vaccine Development - The research team developed an mRNA vaccine targeting ELFN1-AS1 and TYMSOS, which activates anti-tumor immune responses in humanized mouse models, demonstrating significant tumor growth inhibition [6][9]. - The new antigens derived from these genes can induce specific immune responses in patient-derived immune cells, showcasing promising clinical translation potential [6][9].